Organogenesis Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.53
- Today's High:
- $2.675
- Open Price:
- $2.59
- 52W Low:
- $1.795
- 52W High:
- $4.5
- Prev. Close:
- $2.61
- Volume:
- 559690
Company Statistics
- Market Cap.:
- $382.12 million
- Book Value:
- 2.066
- Revenue TTM:
- $457.33 million
- Operating Margin TTM:
- 4.59%
- Gross Profit TTM:
- $345.87 million
- Profit Margin:
- 2.2%
- Return on Assets TTM:
- 2.89%
- Return on Equity TTM:
- 3.82%
Company Profile
Organogenesis Holdings Inc had its IPO on 2017-01-05 under the ticker symbol ORGO.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Organogenesis Holdings Inc has a staff strength of 1,030 employees.
Stock update
Shares of Organogenesis Holdings Inc opened at $2.59 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.53 - $2.68, and closed at $2.64.
This is a +1.15% increase from the previous day's closing price.
A total volume of 559,690 shares were traded at the close of the day’s session.
In the last one week, shares of Organogenesis Holdings Inc have slipped by -9.28%.
Organogenesis Holdings Inc's Key Ratios
Organogenesis Holdings Inc has a market cap of $382.12 million, indicating a price to book ratio of 1.3841 and a price to sales ratio of 0.7167.
In the last 12-months Organogenesis Holdings Inc’s revenue was $457.33 million with a gross profit of $345.87 million and an EBITDA of $33.78 million. The EBITDA ratio measures Organogenesis Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Organogenesis Holdings Inc’s operating margin was 4.59% while its return on assets stood at 2.89% with a return of equity of 3.82%.
In Q2, Organogenesis Holdings Inc’s quarterly earnings growth was a negative -40.7% while revenue growth was a negative 3.4%.
Organogenesis Holdings Inc’s PE and PEG Ratio
- Forward PE
- 12.3153
- Trailing PE
- 36.375
- PEG
Its diluted EPS in the last 12-months stands at $0.08 per share while it has a forward price to earnings multiple of 12.3153 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Organogenesis Holdings Inc’s profitability.
Organogenesis Holdings Inc stock is trading at a EV to sales ratio of 0.8153 and a EV to EBITDA ratio of 7.2311. Its price to sales ratio in the trailing 12-months stood at 0.7167.
Organogenesis Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $450.31 million
- Total Liabilities
- $73.46 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $7.50 million
- Dividend Payout Ratio
- 0%
Organogenesis Holdings Inc ended 2024 with $450.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $450.31 million while shareholder equity stood at $271.28 million.
Organogenesis Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $73.46 million in other current liabilities, 13000.00 in common stock, $-43569000.00 in retained earnings and $28.77 million in goodwill. Its cash balance stood at $88.92 million and cash and short-term investments were $88.92 million. The company’s total short-term debt was $20,363,000 while long-term debt stood at $63.49 million.
Organogenesis Holdings Inc’s total current assets stands at $216.44 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $93.62 million compared to accounts payable of $27.39 million and inventory worth $25.36 million.
In 2024, Organogenesis Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $7.50 million.
Comparatively, Organogenesis Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.64
- 52-Week High
- $4.5
- 52-Week Low
- $1.795
- Analyst Target Price
- $3.5
Organogenesis Holdings Inc stock is currently trading at $2.64 per share. It touched a 52-week high of $4.5 and a 52-week low of $4.5. Analysts tracking the stock have a 12-month average target price of $3.5.
Its 50-day moving average was $3.33 and 200-day moving average was $2.86 The short ratio stood at 2.51 indicating a short percent outstanding of 0%.
Around 4605.1% of the company’s stock are held by insiders while 4169.3% are held by institutions.
Frequently Asked Questions About Organogenesis Holdings Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary wound covering; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company’s pipeline products include PuraPly AM, PuraPly XT, and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.